Skip to main content
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Introduction
Featured Profiles
Genmab
Geron
SpringWorks
Special Series
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Conference Correspondent
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Small Cell Lung Cancer
Evolving Landscapes in Multiple Myeloma
OFS Summit
Multimedia
All Videos
Case-Based Exchanges
Voices From ASCO 2025
Best Practices in Breast Cancer Therapy | OFS
Interview with the Innovators
Rapid Reactions
Webinars
Quick Quiz
Subscribe
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Introduction
Featured Profiles
Genmab
Geron
SpringWorks
Special Series
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Conference Correspondent
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Small Cell Lung Cancer
Evolving Landscapes in Multiple Myeloma
OFS Summit
Multimedia
All Videos
Case-Based Exchanges
Voices From ASCO 2025
Best Practices in Breast Cancer Therapy | OFS
Interview with the Innovators
Rapid Reactions
Webinars
Quick Quiz
Subscribe
FDA Approvals, News & Updates
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
By
Lisa A. Raedler, PhD, RPh
Breast Cancer
,
FDA Approvals, News & Updates
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer
By
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma and for Chronic Graft-versus-Host Disease
By
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates
,
Lymphoma
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Calquence (Acalabrutinib) Approved for Relapsed or Refractory Mantle-Cell Lymphoma in Adults
By
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates
,
Lymphoma
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
By
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates
,
Lung Cancer
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
FDA Approvals of Brand-Name Prescription Cancer Drugs in 2017
FDA Approvals, News & Updates
2018 Third Annual Oncology Guide to New FDA Approvals
The cancer drugs included in this review were approved for the first time or received additional approvals by the US Food and Drug Administration in 2017 and are grouped here by several categories.
Read More ›
FDA Approvals in 2017 Represent a 21-Year High
By
Gary M. Owens, MD
FDA Approvals, News & Updates
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Zytiga Receives New Indication, with Prednisone, for Metastatic, High-Risk Castration-Sensitive Prostate Cancer
FDA Approvals, News & Updates
,
Prostate Cancer
March 2018, Vol 8, No 3
Read More ›
Erleada First Therapy Approved for Patients with Nonmetastatic Castration-Resistant Prostate Cancer
FDA Approvals, News & Updates
March 2018, Vol 8, No 3
Read More ›
Calquence New Treatment Approved for Mantle-Cell Lymphoma
FDA Approvals, News & Updates
December 2017, Vol 7, No 12
Read More ›
Page 33 of 36
30
31
32
33
34
35
36
